These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15621332)

  • 1. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2005 Feb; 43(2):203-16. PubMed ID: 15621332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
    Dorne JL
    Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human variability for metabolic pathways with limited data (CYP2A6, CYP2C9, CYP2E1, ADH, esterases, glycine and sulphate conjugation).
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2004 Mar; 42(3):397-421. PubMed ID: 14871582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human variability in hepatic and renal elimination: implications for risk assessment.
    Dorne JL
    J Appl Toxicol; 2007; 27(5):411-20. PubMed ID: 17497760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism, variability and risk assessment.
    Dorne JL
    Toxicology; 2010 Feb; 268(3):156-64. PubMed ID: 19932147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2003 Feb; 41(2):201-24. PubMed ID: 12480298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans.
    Dorne JL; Renwick AG
    Toxicol Sci; 2005 Jul; 86(1):20-6. PubMed ID: 15800035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2003 Feb; 41(2):225-45. PubMed ID: 12480299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of diuron N-demethylation by mammalian hepatic microsomes and cDNA-expressed human cytochrome P450 enzymes.
    Abass K; Reponen P; Turpeinen M; Jalonen J; Pelkonen O
    Drug Metab Dispos; 2007 Sep; 35(9):1634-41. PubMed ID: 17576805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human variability in the renal elimination of foreign compounds and renal excretion-related uncertainty factors for risk assessment.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2004 Feb; 42(2):275-98. PubMed ID: 14667473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human variability and noncancer risk assessment- An analysis of the default uncertainty factor.
    Renwick AG; Lazarus NR
    Regul Toxicol Pharmacol; 1998 Feb; 27(1 Pt 2):3-20. PubMed ID: 9618319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment.
    Quignot N; Więcek W; Lautz L; Dorne JL; Amzal B
    Toxicol Lett; 2021 Feb; 337():111-120. PubMed ID: 33232775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether acetate.
    Kirman CR; Sweeney LM; Corley R; Gargas ML
    Risk Anal; 2005 Apr; 25(2):271-84. PubMed ID: 15876203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms in assessing interindividual variability in delivered dose.
    Haber LT; Maier A; Gentry PR; Clewell HJ; Dourson ML
    Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):177-97. PubMed ID: 12052003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
    Dorne JL; Walton K; Slob W; Renwick AG
    Food Chem Toxicol; 2002 Nov; 40(11):1633-56. PubMed ID: 12176090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human variability in glucuronidation in relation to uncertainty factors for risk assessment.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2001 Dec; 39(12):1153-73. PubMed ID: 11696390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene.
    Nong A; McCarver DG; Hines RN; Krishnan K
    Toxicol Appl Pharmacol; 2006 Jul; 214(1):78-87. PubMed ID: 16464483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing pediatric dosing: a developmental pharmacologic approach.
    Anderson GD; Lynn AM
    Pharmacotherapy; 2009 Jun; 29(6):680-90. PubMed ID: 19476420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the human kinetic adjustment factor for the health risk assessment of environmental contaminants.
    Valcke M; Krishnan K
    J Appl Toxicol; 2014 Mar; 34(3):227-40. PubMed ID: 24038072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.